Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: ANL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.25% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.42M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 1.10 - 3.89 | Updated Date 09/12/2025 |
52 Weeks Range 1.10 - 3.89 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1220.88% |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -103.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32737481 | Price to Sales(TTM) 34.24 |
Enterprise Value 32737481 | Price to Sales(TTM) 34.24 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 59847067 |
Shares Outstanding 31236900 | Shares Floating 59847067 | ||
Percent Insiders 14.25 | Percent Institutions 0.19 |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on discovering and developing innovative cancer therapies. Founded in 2010, it aims to address unmet medical needs in oncology.
Core Business Areas
- Drug Development: Focuses on researching, developing, and commercializing novel oncology drugs.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Licensing and Partnerships: Establishes partnerships and licensing agreements for collaborative drug development and commercialization.
Leadership and Structure
The leadership team comprises experienced executives in drug development and commercialization. The organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- AN2025: AN2025 is a novel microtubule inhibitor currently in clinical development for various solid tumors. Market share and specific revenue figures are not publicly disclosed. Competitors include companies developing similar microtubule inhibitors, such as Eisai (Halaven), and others using different mechanisms in the same tumor types.
- AN0025: AN0025 is an EP4 antagonist currently in clinical development. Market share and revenue data are not publicly disclosed. Competitors include companies developing EP4 antagonists or therapies targeting the same inflammatory pathways in cancer, such as Kineta.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and rapidly evolving, driven by advancements in cancer biology and technology. There is high demand for novel therapies with improved efficacy and safety profiles.
Positioning
Adlai Nortye positions itself as an innovative player focusing on differentiated cancer therapies, specifically targeting pathways and mechanisms not adequately addressed by existing treatments.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars annually. Adlai Nortye targets specific segments within this market, focusing on indications with high unmet needs and potential for significant market penetration.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Experienced management team
- Strong research and development capabilities
- Strategic partnerships
Weaknesses
- Limited commercial infrastructure
- Dependence on clinical trial outcomes
- High cash burn rate
- Reliance on external funding
Opportunities
- Successful clinical trial results
- Expansion into new markets
- Strategic acquisitions or partnerships
- Regulatory approvals for lead drug candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Adlai Nortye faces intense competition from larger, established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on the differentiation and clinical efficacy of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available as it's a relatively young company.
Future Projections: Future growth projections are reliant on successful clinical trials and subsequent regulatory approvals. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include advancing clinical trials for AN2025 and AN0025, seeking strategic partnerships, and expanding research programs.
Summary
Adlai Nortye is a biopharmaceutical company with innovative drug candidates in oncology, but it faces challenges due to its limited resources and reliance on clinical trial success. Its strengths lie in its R&D and strategic partnerships, while weaknesses include its limited commercial infrastructure and high cash burn rate. The company needs to focus on securing funding and achieving positive clinical trial outcomes to capitalize on its opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | Co- Founder, CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.adlainortye.com |
Full time employees 123 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.